What is the latest DCAL stock price?
The latest stored price for DCAL is Rs 190.19 as of 2026-07-21.
gimli
DCAL stock AI analysis
DCAL Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
DISHMAN CARBO AMCIS LTD is a small-cap stock in Healthcare. This Gimli page shows the latest available DCAL price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹190.19
1W return
-2.44%
1M return
+11.40%
3M return
+12.17%
6M return
-12.68%
1Y return
-25.97%
Market cap
₹2,981.86 cr
PE
30.60
PB
0.45
ROE
+1.56%
ROCE
+2.29%
RSI
52.62
Turnover
₹2.59 cr
Why it can matter in screens
- Momentum: DCAL is above 50DMA, below 200DMA; RSI is 52.62.
- Returns: 1D -0.34%, 1W -2.44%, 1M +11.40%, 3M +12.17%, 1Y -25.97%.
- Trend levels: 52W high ₹314.40, 52W low ₹129.97, off high -39.51%.
- Liquidity: latest turnover is ₹2.59 cr; volume vs 20D is +0.32%.
- Valuation/profitability: PE 30.60, PB 0.45, ROE +1.56%, ROCE +2.29%.
- Growth: 3Y sales CAGR +8.19%, 3Y profit CAGR n/a.
Quick Answers
Is DCAL above its 50DMA and 200DMA?
DCAL is above 50DMA, below 200DMA. The latest 50DMA is 187.28 and the latest 200DMA is 212.75.
What are DCAL PE, ROE and ROCE?
DCAL has PE 30.60, ROE +1.56%, and ROCE +2.29% in Gimli's latest available snapshot.
How has DCAL performed recently?
DCAL has returned +11.40% over 1 month, +12.17% over 3 months, and -25.97% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 851.40 cr | 178.22 cr | 21.74 cr | 1.39 |
| 2025-12-31 | 719.80 cr | 119.77 cr | -12.97 cr | -0.83 |
| 2025-09-30 | 660.76 cr | 157.00 cr | 65.27 cr | 4.16 |
| 2025-06-30 | 708.05 cr | 162.78 cr | 23.41 cr | 1.49 |
| 2025-03-31 | 716.34 cr | 148.91 cr | 43.09 cr | 2.75 |
| 2024-12-31 | 682.34 cr | 147.80 cr | 4.63 cr | 0.30 |
| 2024-09-30 | 789.04 cr | 150.84 cr | n/a | nan |
| 2024-06-30 | 523.78 cr | 24.96 cr | -77.57 cr | -4.95 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 2,931.90 cr | 617.77 cr | 97.45 cr | 6.22 |
| 2025-03-31 | 2,711.50 cr | 472.51 cr | 3.24 cr | 0.21 |
| 2024-03-31 | 2,543.62 cr | 302.01 cr | -153.45 cr | -9.79 |
| 2023-03-31 | 2,315.05 cr | 300.52 cr | -29.80 cr | -1.90 |
| 2022-03-31 | 367.00 cr | 342.56 cr | -30.47 cr | -2.01 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 11,923.31 cr | 787.76 cr | 3,076.06 cr | 6,676.90 cr |
| 2025-03-31 | 9,999.15 cr | 341.07 cr | 2,388.95 cr | 5,831.52 cr |
| 2024-03-31 | 9,581.41 cr | 264.09 cr | 2,312.60 cr | 5,627.50 cr |
| 2023-03-31 | 9,453.50 cr | 131.79 cr | 2,208.85 cr | 5,809.67 cr |
| 2022-03-31 | 8,637.45 cr | 110.24 cr | 1,829.89 cr | 5,548.94 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 491.45 cr | 224.84 cr | n/a |
| 2025-03-31 | 371.28 cr | 154.52 cr | n/a |
| 2024-03-31 | 379.43 cr | 76.18 cr | n/a |
| 2023-03-31 | 265.95 cr | -353.73 cr | n/a |
| 2022-03-31 | 354.85 cr | -108.95 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-03-31 | +59.32% | +7.45% | +1.63% | +1.06% | +31.60% | +0.00% |
| 2025-12-31 | +59.32% | +7.66% | +1.27% | +1.08% | +31.75% | +0.00% |
| 2025-09-30 | +59.32% | +8.07% | +1.37% | +1.08% | +31.23% | +0.00% |
| 2025-06-30 | +59.32% | +9.93% | +1.27% | +1.07% | +29.47% | +0.00% |
| 2025-03-31 | +59.32% | +9.49% | +1.26% | +1.06% | +29.93% | +0.00% |
| 2024-12-31 | +59.32% | +8.75% | +1.42% | +1.22% | +30.51% | +0.00% |
| 2024-09-30 | +59.32% | +8.17% | +1.23% | +1.03% | +31.28% | +0.00% |
| 2024-06-30 | +59.32% | +8.04% | +1.47% | +1.28% | +31.16% | +0.00% |
| 2024-03-31 | +59.32% | +8.70% | +2.37% | +2.17% | +29.61% | +0.00% |
| 2023-12-31 | +59.32% | +8.61% | +3.69% | +3.45% | +28.39% | +0.00% |
| 2023-09-30 | +59.32% | +8.80% | +3.52% | +3.28% | +28.36% | +0.00% |
| 2023-06-30 | +59.32% | +8.90% | +3.14% | +2.90% | +28.64% | +0.00% |
| 2023-03-31 | +59.32% | +9.34% | +2.56% | +2.32% | +28.78% | +0.00% |
| 2022-12-31 | +59.32% | +7.20% | +3.87% | +3.63% | +29.61% | +0.00% |
| 2022-09-30 | +59.32% | +6.20% | +4.28% | +4.26% | +30.20% | +0.00% |
| 2022-06-30 | +59.32% | +0.00% | +12.48% | n/a | n/a | +0.00% |
| 2022-03-31 | +59.32% | +0.00% | +12.41% | n/a | n/a | +0.00% |
| 2021-12-31 | +59.32% | +0.00% | +10.91% | n/a | n/a | +0.00% |
| 2021-09-30 | +59.32% | +0.00% | +10.55% | n/a | n/a | +0.00% |
| 2021-06-30 | +59.32% | +0.00% | +12.66% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 470,725.53 cr | 40.938102 | +14.71% | +15.93% |
| DIVISLAB | DIVI S LABORATORIES LTD | 194,588.48 cr | 75.774332 | +16.19% | +9.60% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 170,600.17 cr | 78.872017 | +17.18% | +43.04% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,349.41 cr | 65.537894 | +21.03% | +23.05% |
| CIPLA | CIPLA LTD | 115,717.42 cr | 29.815932 | +11.79% | -2.81% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 115,022.61 cr | 22.938459 | +17.93% | +17.85% |
| LUPIN | LUPIN LIMITED | 114,980.65 cr | 21.532280 | +26.83% | +30.91% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 107,095.75 cr | 74.247785 | +14.33% | -9.67% |
Try these prompts
- Analyze DISHMAN CARBO AMCIS with valuation, momentum and industry peers
- Compare DCAL with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare DCAL with other Healthcare stocks
Data snapshot: 2026-07-21. Not investment advice.